lung

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca

Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI...

Bio & Pharma Yuhan’s lung cancer drug clears FDA hurdle for global debut

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

Bio & Pharma Lunit participates in US gov't Cancer Moonshot

South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moon...

Bio & Pharma S.Korea’s Coreline Soft teams up with HCK of Switzerland

South Korea's Coreline Soft, a maker of artificial intelligence (AI)-based imaging diagnostic materials, on Wednesday said it will sell its chest di...

Bio & Pharma S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug

South Korea's Qurient Co. announced on Monday that it signed a research and development agreement with the US government agency National Cancer Inst...

Bio & Pharma Clinomics releases equipment that quickly finds lung cancer mutations

Clinomics, a South Korean biotech company specializing in liquid biopsies, on Thursday said it developed equipment that can detect four types of l...

Bio & Pharma Bridge Biotherapeutics, Pinotbio develop lung cancer treatment

South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...

Bio & Pharma Celltrion wins sales approval for biosimilar Vegzelma in Japan

Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...

Bio & Pharma Korea Hanmi to launch blockbuster hypertension drug in China

South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...